CTLA4 and cancer: In conclusion, the current study shows a connection between downregulation of miR-146 with increased serum levels of TGF-β.Thus, blocking TGF-β using monoclonal antibodies may potentiate the effects of ICIs such as CTLA4 blockers, resulting in an immune brake, enhancing T-cell cytotoxicity and enhancing cancer cell killing.